HealthDay News — Statin use is associated with a reduced risk of all-cause and pulmonary-related mortality in patients with chronic obstructive pulmonary disease (COPD), according to a study published online in Chest.
Adam Raymakers, from the University of British Columbia in Canada, and colleagues evaluated the association of statin use with all-cause and pulmonary-related mortality in patients with COPD. They used individual prescription records to identify 39,678 COPD patients, of whom 7775 had received at least 1 statin in the 1-year period after COPD diagnosis.
The researchers found that there were 1446 all-cause deaths recorded within the cohort in the 1-year exposure window.
In multivariate analysis, the estimated hazard ratio for statin exposure was 0.79, suggesting a 21% reduction in the risk of all-cause mortality. There was also a considerable reduction in the risk for pulmonary-related mortality (HR, 0.55).
“This study shows that statin use in a population-based cohort of COPD patients may confer benefits in terms of reduced pulmonary-related and all-cause mortality,” conclude the authors.
One author reports financial ties to the pharmaceutical industry.
Raymakers AJN, Sadatsafavi M, Sin DD, De Vera MA, Lynd LD. The impact of statin drug use on all-cause mortality in patients with COPD: a population-based cohort study. Chest. 2017;152(3):486-493.